AI spending risks and OpenAI's plan to mine biotech failures
A finance professor's analysis indicates AI companies must achieve extraordinary productivity gains to justify nearly $1.1 trillion in data center spending by 2027. Separately, the OpenAI Foundation will fund a project to create scientific datasets from failed biotech companies' regulatory filings. The initiative aims to provide AI systems with more biological data to accelerate medical breakthroughs.
The financial analysis centers on hyperscalers' projected capital expenditures, which are expected to approach $1.1 trillion by 2027. To make this investment viable, these companies would need to generate extraordinary productivity gains by 2030, a benchmark that appears daunting given current economic uncertainties. The analysis deliberately avoids predicting AI adoption rates, instead focusing on the earnings growth required to offset the massive infrastructure costs.
Separately, the OpenAI Foundation is funding a project to acquire regulatory filings and manufacturing data from bankrupt biotech firms. The initiative originated from a policy analyst's proposal to create "biotech's lost archive" by bidding at bankruptcy proceedings. This data would be used to create high-quality scientific datasets, potentially giving AI systems access to biological information that would otherwise remain inaccessible.
This dual development could reshape both the technology and healthcare sectors. If AI companies fail to achieve the required productivity gains, investors may face significant losses, potentially dampening future infrastructure investment. Conversely, the biotech data initiative could accelerate medical research, though it raises questions about data ownership and the use of proprietary information from failed companies. Patients may ultimately benefit from faster drug development, but the financial risks could have broader economic implications.